

Amendments to the CLAIMS:

1. – 29. (cancelled).

30. (previously presented) An azabicyclic derivative, which is
2,2'-Bis-((\pm)-1-aza-bicyclo[2.2.2]oct-3-yloxy)-[5,5']-bithiazolyl;
2,2'-Bis-((\pm)-1-aza-bicyclo[2.2.2]oct-3-yloxy)-[5,5']-bifuranyl;
6,6'-Bis-((\pm)-1-aza-bicyclo[2.2.2]oct-3-yloxy)-[3,3']-bipyridinyl;
6,6'-Bis-((\pm)-1-aza-bicyclo[2.2.2]oct-3-yloxy)-[3,3']-bipyridazinyl; or
6-[4-(1-Aza-bicyclo[2.2.2]oct-3-yloxy)-phenyl]-pyridazin-3-ol-(1-aza-bicyclo[2.2.2]oct-3-yl);
or an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable
addition salt thereof, or an onium salt thereof.

31. (cancelled).

32. (previously presented) An azabicyclic derivative, which is
6,6'-Bis-[1,4]-diaza-bicyclo[3.2.2]nonan-1-yl-[3,3']-bipyridazinyl;
1,2-Di-[6-(1,4-diaza-bicyclo[3.2.2]nonan-4-yl)-pyridazin-3-yl-thio]-benzene; or
1,3-Di-[6-(1,4-diaza-bicyclo[3.2.2]nonan-4-yl)-pyridazin-3-yl-thio]-benzene;
or an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable
addition salt thereof, or an onium salt thereof.


33. – 43. (cancelled).

44. (previously presented) An azabicyclic derivative represented by Formula I




an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable addition
salt thereof, or an onium salt thereof, wherein,

AZA represents an azacyclic group selected from



and




wherein n is 0, 1, 2 or 3 and m is 1 or 2;

X' and X'' are absent (i.e. represent single (covalent) bonds); or X' and X'' represent -O-, -S-, -SO-, -NH-, or -(CO)-; and

A' and A'' represent phenyl, pyridyl, thienyl, furanyl, pyridazinyl and/or thiazolyl; and

Y', Y'' and L represent single (covalent) bonds; or Y' and Y'' represent -O-, -S-, -SO- or -NH-; and L represents a phenyl group.

45. (withdrawn) The compound of claim 44, an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof, wherein AZA represents the azacyclic group



wherein n is 1 and m is 1; X' and X'' are absent (i.e. represent single (covalent) bonds); and A' and A'' represent pyridazinyl; and Y', Y'' and L represent single (covalent) bonds.


46. (previously presented) The compound of claim 44, which is 6,6'-bis-[1,4]-diaza-bicyclo[3.2.2]nonan-1-yl-[3,3']-bipyridazinyl, or an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof.

47. (currently amended) An azabicyclic derivative represented by Formula I




an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof, wherein,

AZA represents an azacyclic group selected from



and



wherein n is 1 and m is 2;

X' and X'' represent single (covalent) bonds;

A' and A'' represent pyridazinyl or thiazolyl; and


Y', Y'', and L represent single (covalent) bonds,

said azabicyclic derivative thus corresponding to the simplified formula



48. (previously presented) The azabicyclic derivative of claim 47, wherein,

AZA represents the azacyclic group




49. (previously presented) An azabicyclic derivative represented by Formula I




an enantiomer thereof, or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof, wherein,

AZA represents an azacyclic group selected from




and



wherein n is 1 and m is 2; X' and X'' represent single (covalent) bonds; A' and A'' represent pyridazinyl or thiazolyl; Y' and Y'' represent -O-, -S-, -SO-, or -NH-; and L represents a phenyl group.

50. (previously presented) The azabicyclic derivative of claim 49, wherein,

AZA represents the azacyclic group



51. (previously presented) The azabicyclic derivative of claim 50, wherein Y' and Y'' represent -O- or -S-.

52. (previously presented) The azabicyclic derivative of claim 51, wherein A' and A'' represent pyridazinyl.